• Feel Good Friday Client Spotlight: Willms Family

    Feel Good Friday Client Spotlight: Willms Family

    For this week’s #ClientSpotlight, we are excited to feature the Willms family! During COVID-19, parents Josh and Alisha have been keeping busy by creating a more accessible bathroom for their son Emmett to use and grow into. They built a roll-in shower, and an accessible sink to give Emmett more independence and safety in the …Continue Reading
  • Feel Good Friday Client Spotlight: Ken M. Kramer

    Feel Good Friday Client Spotlight: Ken M. Kramer

    For this week’s #ClientSpotlight, we are proud to feature Ken M. Kramer, QC. Ken is the Principal & Senior Associate Counsel for KMK Law, and was also the first person with a neuromuscular disorder to lead Muscular Dystrophy Canada as Chair of the Board of Directors. Ken is an advocate for accessibility and inclusion both …Continue Reading
  • National Volunteer Week 2020

    National Volunteer Week 2020

    Muscular Dystrophy Canada is a volunteer-driven organization. We rely on dedicated, enthusiastic, diverse and dynamic people to help us meet our mission – from clients to family members, community supporters to like-minded organizations, and healthcare professionals to Fire Fighters and beyond. All of our volunteers are key partners in the delivery of MDC’s support programs, …Continue Reading
  • COVID – 19: What you should know about this novel coronavirus

    COVID – 19: What you should know about this novel coronavirus

    Given the recent updates on COVID-19, Muscular Dystrophy Canada has implemented a work from home policy, therefore, effective immediately all MDC offices are closed. Our staff remain available via email and telephone and will continue to serve our clients, volunteers, donors and other key stakeholders. During this difficult time, we remind everyone that social distancing …Continue Reading
  • Response to PMPRB Draft Guidelines Consultation

    Response to PMPRB Draft Guidelines Consultation

    February 14, 2020 Dr. Mitchell Levine Chairperson Patented Medicines Prices Review Board 333 Laurier Avenue West, Suite 1400 Ottawa, Ontario K1P 1C1 Email: PMPRB.Consultations.CEPMB@pmprb-cepmb.gc.ca Dear Dr. Levine: Muscular Dystrophy Canada is thankful for the invitation to attend the PMPRB Consultation meeting in Ottawa on December 10, 2019 and for the opportunity to respond to the …Continue Reading
  • Key topics in Spinal Muscular Atrophy research discussed at first ever Muscular Dystrophy Canada SMA Research Summit

    Key topics in Spinal Muscular Atrophy research discussed at first ever Muscular Dystrophy Canada SMA Research Summit

    Toronto, November 15, 2019 – Research experts, the medical community, and industry stakeholders came together in Toronto this week at the inaugural Muscular Dystrophy Canada (MDC) SMA Research Summit to discuss new research and development. “This summit was an important opportunity for us to review the latest developments and discuss where there are opportunities to …Continue Reading
  • Major Improvement in CRISPR Technology Could Fix Genetic Spelling Mistakes: Implications for Neuromuscular Disorders?

    Major Improvement in CRISPR Technology Could Fix Genetic Spelling Mistakes: Implications for Neuromuscular Disorders?

    CRISPR-Cas9 technology, a gene editing tool, has been significantly upgraded with a new feature called prime editing. This enhancement addresses two limitations of CRISPR technology by: (1) allowing the change of a gene’s spelling into a predicted sequence without requiring a cell to divide and (2) without needing to cut both strands of the DNA …Continue Reading
  • Alberta Fourth Province to Expand Access to Spinraza™ for Patients Impacted with Spinal Muscular Atrophy

    Alberta Fourth Province to Expand Access to Spinraza™ for Patients Impacted with Spinal Muscular Atrophy

    Alberta fourth province to expand access to SPINRAZA™ for patients impacted with Spinal Muscular Atrophy. Muscular Dystrophy Canada (MDC) commends the Government of Alberta for joining Quebec, Saskatchewan, and Ontario in expanding access to SPINRAZA™, a life-changing treatment for individuals impacted with Spinal Muscular Atrophy (SMA). In Alberta, the following patients will now be eligible …Continue Reading
  • More Patients Impacted with Spinal Muscular Atrophy in Ontario to Gain Access to Spinraza™

    More Patients Impacted with Spinal Muscular Atrophy in Ontario to Gain Access to Spinraza™

    Toronto, Ontario – Muscular Dystrophy Canada (MDC) applauds the Government of Ontario for expanding access to SPINRAZA™, a life-changing treatment for individuals impacted with Spinal Muscular Atrophy (SMA). In Ontario, expanded coverage of SPINRAZA™ will include the following, in addition to existing coverage for Type 1 patients: patients who are pre-symptomatic with two or three …Continue Reading
  • Patients Living with Spinal Muscular Atrophy (SMA) in the Province of Saskatchewan Gain Access to Spinraza™

    Patients Living with Spinal Muscular Atrophy (SMA) in the Province of Saskatchewan Gain Access to Spinraza™

    April 22, 2019 Dear members of the SMA community, In response to the requests received by patients living with Spinal Muscular Atrophy (SMA), Biogen Canada would like to provide this latest progress regarding coverage of SPINRAZA™ (nusinersen) in the province of Saskatchewan. Biogen Canada is delighted to inform you that on April 12, 2019, the …Continue Reading